DH Definitive Healthcare Corp.
Services-Prepackaged Software · Nasdaq · SEC CIK 1861795 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.2%
TTM net income YoY16.7%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-2.6%
Net income 3-yr CAGR—
Margins
Gross margin75.4%
Operating margin-105.4%
Net margin-69.2%
FCF margin10.6%
EBITDA margin-96.9%
Returns
ROE-73.1%
ROA-25.3%
ROIC (approx.)-80.5%
Asset turnover0.37x
Leverage & solvency
Liabilities / assets61.4%
Debt / equity1.09x
Current ratio1.96x
Interest coverage-22.22x
Cash quality & payout
Operating cash flow / net income-0.24x
Accruals ratio-31.3%
Payout ratio—
Capex / revenue5.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $241.52M | $252.20M |
| Cost of revenue | $58.25M | $54.73M |
| Gross profit | $183.28M | $197.47M |
| R&D expense | $34.78M | $36.52M |
| SG&A expense | $51.63M | $49.27M |
| Operating income | -$224.27M | -$710.82M |
| Interest expense | $11.29M | $14.84M |
| Pretax income | -$209.26M | -$633.75M |
| Income tax | -$9.96M | -$42.30M |
| Net income | -$138.93M | -$413.12M |
| EBITDA | -$220.97M | -$708.58M |
| EPS (basic) | -1.30 | -3.54 |
| EPS (diluted) | -1.30 | -3.54 |
| Weighted avg. shares (diluted) | 106.65M | 116.64M |
| Balance sheet | ||
| Cash & equivalents | $163.63M | $105.38M |
| Short-term investments | $17.26M | $184.79M |
| Receivables | $51.98M | $53.20M |
| Current assets | $257.61M | $370.17M |
| PP&E, net | $12.68M | $3.79M |
| Goodwill | $197.22M | $393.28M |
| Intangibles | $247.48M | $297.93M |
| Total assets | $735.49M | $1.09B |
| Current liabilities | $156.79M | $161.16M |
| Short-term debt | $8.75M | $13.75M |
| Long-term debt | $156.09M | $229.37M |
| Total debt | $164.84M | $243.12M |
| Total liabilities | $356.50M | $482.19M |
| Shareholders' equity | $281.11M | $444.38M |
| Net debt | $1.21M | $137.74M |
| Cash flow statement | ||
| Operating cash flow | $53.78M | $58.20M |
| Capital expenditure | $16.72M | $12.34M |
| Free cash flow | $37.06M | $45.85M |
| Investing cash flow | $153.88M | -$26.41M |
| Financing cash flow | -$150.79M | -$56.75M |
| Depreciation & amortization | $3.30M | $2.25M |
| Stock-based compensation | $29.14M | $38.09M |
| Share buybacks | $49.45M | $22.37M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.